Article · 5 Oct 2026
Conference abstract
Strategies and innovation in biosimilar drug development, achievement and challenges ? An Indian perspective
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Hatim Motiwala is a postgraduate in Microbiology and at completion stage of Ph.D. from The M.S. University of Baroda, India. He has 12 years of experience working on biosimilars. His core expertise is in mammalian cell culture with working experience in cell line development, mammalian upstream process development, in-vitro bioassays, technology evaluation and transfer. Currently, working at a post of Senior Scientist and managing three biosimilar monoclonal antibody development programs at Intas Biopharmaceutical Limited. Earlier he was associated with Biocon Biopharmaceuticals, Cadila Pharmaceuticals, Sun Pharma Advanced Research Centre, and Chiron Vaccines Limited (Aventis).
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Villoo Morawala-Patell”